The Journal of Biomedical Research2024，Vol.38Issue(2)：P.149-162,I0001-I0010,24.DOI:10.7555/JBR.37.20230049
Genetic variant in a BaP-activated super-enhancer increases prostate cancer risk by promoting AhR-mediated FAM227A expression
Lulu Fan 1Hao Wang 1Shuai Ben 1Yifei Cheng 1Silu Chen 1Zhutao Ding 1Lingyan Zhao 1Shuwei Li 1Meilin Wang 1Gong Cheng2
作者信息
- 1. Department of Environmental Genomics,Jiangsu Key Laboratory of Cancer Biomarkers,Prevention and Treatment,Collaborative Innovation Center for Cancer Personalized Medicine,School of Public Health,Nanjing Medical University,Nanjing,Jiangsu 211166,China Department of Genetic Toxicology,the Key Laboratory of Modern Toxicology of Ministry of Education,Center for Global Health,School of Public Health,Nanjing Medical University,Nanjing,Jiangsu 211166,China
- 2. Department of Urology,the First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing,Jiangsu 210029,China
- 折叠
摘要
关键词
super-enhancer/prostate cancer/genetic variants/AhR/BaP/FAM227A分类
医药卫生引用本文复制引用
Lulu Fan,Hao Wang,Shuai Ben,Yifei Cheng,Silu Chen,Zhutao Ding,Lingyan Zhao,Shuwei Li,Meilin Wang,Gong Cheng..Genetic variant in a BaP-activated super-enhancer increases prostate cancer risk by promoting AhR-mediated FAM227A expression[J].The Journal of Biomedical Research,2024,38(2):P.149-162,I0001-I0010,24.
